Alkermes (ALKS) Interest & Investment Income (2010 - 2026)
Alkermes (ALKS) reported Interest & Investment Income of $8.5 million for Q1 2026, down 15.8% year-over-year from $10.1 million in Q1 2025, and down 29.6% quarter-over-quarter from $12.1 million in Q4 2025.
Alkermes (ALKS) Interest & Investment Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Interest & Investment Income data on file, last reported at $8.5 million in Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $8.5 million, down 15.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.7 million (up 1.18% YoY), and the FY2025 annual result was $45.3 million, up 6.72% from the prior year.
- Interest & Investment Income eased to $8.5 million in Q1 2026 per ALKS's latest filing, from $12.1 million in the prior quarter.
- Over five years, Interest & Investment Income peaked at $12.1 million in Q4 2025 and troughed at $573000.0 in Q1 2022.
- A 5-year average of $7.9 million and a median of $9.4 million in 2024 frame the typical range for Interest & Investment Income.
- The sharpest annual moves came in 2022 and 2023: Interest & Investment Income tumbled 33.68% in 2022, then jumped 766.67% in 2023.
- A 5-year view of Interest & Investment Income shows it stood at $3.9 million in 2022, then jumped by 148.64% to $9.7 million in 2023, then grew by 16.94% to $11.4 million in 2024, then advanced by 6.4% to $12.1 million in 2025, then fell by 29.6% to $8.5 million in 2026.
- Business Quant data shows ALKS's Interest & Investment Income at $8.5 million in Q1 2026, $12.1 million in Q4 2025, and $11.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn | - |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn | - |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn | 41.80 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn | 3.45 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn | 28.10 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn | - |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn | 8.54 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn | 4.97 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn | - |
| 10 | Liquidia | 5.74 Bn | 5.52 Bn | 121.79 Mn | 1.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.54 Mn |
| Dec 31, 2025 | 12.13 Mn |
| Sep 30, 2025 | 11.94 Mn |
| Jun 30, 2025 | 11.09 Mn |
| Mar 31, 2025 | 10.14 Mn |
| Dec 31, 2024 | 11.40 Mn |
| Sep 30, 2024 | 10.92 Mn |
| Jun 30, 2024 | 10.74 Mn |
| Mar 31, 2024 | 9.40 Mn |
| Dec 31, 2023 | 9.75 Mn |
| Sep 30, 2023 | 9.37 Mn |
| Jun 30, 2023 | 6.77 Mn |
| Mar 31, 2023 | 4.97 Mn |
| Dec 31, 2022 | 3.92 Mn |
| Sep 30, 2022 | 2.24 Mn |
| Jun 30, 2022 | 896,000.00 |
| Mar 31, 2022 | 573,000.00 |
| Dec 31, 2021 | 453,000.00 |
| Sep 30, 2021 | 468,000.00 |
| Jun 30, 2021 | 623,000.00 |